Juvenile Dermatomyositis – ein interessanter Fall aus der Klinik

• Literatur

• 1 Salles Rosa Neto N. et al. Juvenile dermatomyositis: review and update of the pathogenesis and treatment. Bras J Rheumatol 2010; 50 (03) 299-312.
• 2 Compeyrot-Lacassagne S. et al. Inflammatory myopathies in children. Pediatr Clin North Am 2005; 52: 493-520.
• 3 Weddenburn LR. et al. Paediatric idiopathic inflammatory muscle disease. Best Pract Res Clin Rheumatol 2001; 18: 345-358.
• 4 Kim S. et al. Complete ans sustained remission of juvenile Dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009; 60 (06) 1825-1830.
• 5 Sallum AM. et al. Risk factors associated with cacinosis of juvenile Dermatomyositis. J Pediatr (Rio J) 2008; 84: 68-74.
• 6 Stringer E. et al. Predicting the course of juvenile dermatomyositis: significance of early laboratory and clinical features. Arthritis Rheum 2008; 58: 3585-3592.
• 7 Lovell DJ, Lindsley CB, Rennebohm RM. et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Acitivity Collaborative Study Group. Arthritis Rheum 1999; 42: 2213.
• 8 Iaccorino L. et al. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?. Autoimmun Rev 2007; 6 (03) 190-195.
• 9 de Oliviera SK. et al. Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center. Acta Reumatol Port 2007; 32 (02) 139-150.
• 10 Maillard SM. et al. The treatment of persistant idiopathic inflammatory myositis with anti-TNFalpha therapy. Arthritis Rheum 2002; 46 (Suppl) S307.